Sofpromed, a European full service contract research organization (CRO) specializing in the integral management of phase I-IV clinical trials in oncology, has selected TrialMaster as their preferred electronic data capture (EDC) system to support their clinical data management services. TrialMaster is one of the primary eClinical software solution offerings from OmniComm Systems, Inc., an Anju Software company and a global provider of clinical data management technology. In addition to data management services, Sofpromed specializes in providing oncology-focused clinical trial services for studies in solid tumors and hematologic malignancies for the pharmaceutical and biotechnology industries.
“As an oncology-focused CRO, we are pleased to provide Omnicomm’s TrialMaster EDC solution to our customers, particularly to pharma and biotech companies conducting phase I-IV clinical studies for the development of cancer drugs in the United States and Europe,” said Patricio Ledesma, Sofpromed’s chief executive officer (CEO). He continued, “[The] TrialMaster EDC Suite will greatly enrich and strengthen our data management and statistical programming services for clinical trials. Sponsors will benefit from solid, high quality clinical data, while investigators and study coordinators will certainly value TrialMaster’s intuitive design and ease of use.”
As a full-service provider of clinical trial management services across Europe, Sofpromed aims to help customers accelerate study start-up, recruitment, and data analysis by offering oncological and regulatory expertise, as well as technical proficiency. Sofpromed considers the data management and reporting features of TrialMaster to be of particular value to support their operations. CEO Ledesma stated, “With TrialMaster’s ad hoc report tool our data managers will be able to generate dynamic reports, such as patient profiles, recruitment, and form status. In addition, the system’s built-in data mapping and export tools will further improve our capabilities to quickly produce robust SDTM datasets for FDA submissions, which is an absolutely critical need for the pharmaceutical industry.”
“We are delighted to partner with Sofpromed to conduct their oncology trials,” said Rohit Mistry, OmniComm’s senior vice president of business development for the EMEA region. “The studies they conduct are complex in nature, requiring an EDC that provides flexibility, yet still very intuitive for sites globally to use. With the support of our European delivery team, Sofpromed is now enabled to incorporate TrialMaster study build services into their core services, offering sponsors their oncological expertise coupled with the most innovative EDC solution on the market.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.